Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 41Myeloproliferative Disorders 30Polycythemia Vera 28Leukemia, Myeloid, Acute 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 17Myelodysplastic Syndromes 15Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 9Multiple Myeloma 9Graft vs Host Disease 9Breast Neoplasms 9Pancreatic Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hematologic Neoplasms 6Prostatic Neoplasms 5Lymphoma, T-Cell 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Hodgkin Disease 5Hematologic Diseases 5Colorectal Neoplasms 5Thrombocytosis 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Carcinoma, Non-Small-Cell Lung 4

Interventions

dacetuzumab 2Bortezomib 2sonidegib 1ruxolitinib 1ficlatuzumab 1Vorinostat 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Lenalidomide 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhagic Disorders × ruxolitinib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡